# Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve/ The SAPIEN 3 Study

Study · id `cardio:ct-nct01808287` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01808287](<https://clinicaltrials.gov/study/NCT01808287>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01808287

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.

## Technical summary

Registry record NCT01808287. Non-randomized; no masking; primary purpose treatment. Start 2013-01 (actual); primary completion 2013-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 250 participants (enrolled count; ClinicalTrials.gov record NCT01808287, source copy `cardio:ctgov-nct01808287-2020-04-01`, retrieved 2026-10-26)
- Started: 2013-01 (actual) (ClinicalTrials.gov record NCT01808287, source copy `cardio:ctgov-nct01808287-2020-04-01`, retrieved 2026-10-26)
- Primary completion: 2013-12 (actual) (ClinicalTrials.gov record NCT01808287, source copy `cardio:ctgov-nct01808287-2020-04-01`, retrieved 2026-10-26)
- Completion: 2019-12-17 (actual) (ClinicalTrials.gov record NCT01808287, source copy `cardio:ctgov-nct01808287-2020-04-01`, retrieved 2026-10-26)
- Countries: Canada; France; Germany; Italy; United Kingdom (ClinicalTrials.gov record NCT01808287, source copy `cardio:ctgov-nct01808287-2020-04-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01808287-2020-04-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve/ The SAPIEN 3 Study
- Acronym: SAPIEN3
- Condition: Aortic Valve Disease
- Intervention (Device): Edwards SAPIEN 3 Transcatheter Heart Valve
- Lead sponsor: Edwards Lifesciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Edwards Lifesciences (`cardio:edwards-lifesciences`)

## Provenance

Content hash: ff3a12157a42e6a4fefe4017c6099cd36193593c8ead210c9b298612727ced0a
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
